drugset / Trial / NCT03313336

A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.

NCT03313336 ↗

Phase 1 Completed 32 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverDouble-blindSupportive care

Summary

A double-blind, randomized, 2-period, placebo-controlled, single-center, crossover study, efficacy study demonstrating the therapeutic equivalence of the test cellulose disc (matrix) in EMLA patch and the current commercial cellulose disc (matrix) in EMLA patch in healthy subjects.

Timeline

Start
2017-10-30
Primary completion
2017-11-09
Completion
2017-11-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified — —
Comparator prilocaine Small molecule — —

Indications

No indication recorded.